Indivior
Indivior PLC, a global leader in addiction treatment, is headquartered in the United States and operates extensively across North America and Europe. Founded in 2014, the company has rapidly established itself within the pharmaceutical industry, focusing on innovative solutions for opioid dependence and other substance use disorders. Indivior is renowned for its flagship product, Suboxone, which combines buprenorphine and naloxone to effectively manage opioid addiction while minimising misuse potential. This unique formulation has positioned Indivior as a key player in the market, contributing to significant advancements in addiction therapy. With a commitment to improving patient outcomes, Indivior has achieved notable milestones, including regulatory approvals and partnerships that enhance its service offerings. The company continues to lead the way in addressing the global opioid crisis, solidifying its reputation as a trusted provider in the addiction treatment sector.
DitchCarbon Score
How does Indivior's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Indivior's score of 53 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Indivior's reported carbon emissions
In 2023, Indivior reported total carbon emissions of approximately 8,604,000 kg CO2e, with significant contributions from Scope 1, Scope 2, and Scope 3 emissions. Specifically, Scope 1 emissions were about 4,573,000 kg CO2e, while Scope 2 emissions totalled approximately 2,366,000 kg CO2e. The majority of emissions stemmed from Scope 3, which accounted for about 107,779,000 kg CO2e, highlighting the substantial impact of their supply chain and product lifecycle. In 2024, Indivior's total emissions decreased to approximately 4,102,000 kg CO2e, with Scope 1 emissions at about 698,600 kg CO2e and Scope 2 emissions around 5,174,000 kg CO2e. Scope 3 emissions remained significant, totalling approximately 129,350,000 kg CO2e. Indivior has set ambitious long-term climate commitments, aiming for net-zero emissions by 2050 for both Scope 1 and Scope 2 emissions. This commitment is contingent on a globally coordinated effort towards decarbonisation, starting from 2023. The company is actively working towards these targets, reflecting a proactive approach to climate change and sustainability within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 699,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 2,592,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 140,000 | 000,000 | 0,000,000 | 0,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Indivior is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
